Liver abnormalities following SARS-CoV-2 infection in children under 10 years of age

Publication date: Sep 22, 2023

Objective: Beginning in October 2021 in the US and elsewhere, cases of severe pediatric hepatitis of unknown etiology were identified in young children. While the adenovirus and adenovirus-associated virus have emerged as leading etiologic suspects, we attempted to investigate a potential role for SARS-CoV-2 in the development of subsequent liver abnormalities. Design: We conducted a study utilizing retrospective cohorts of de-identified, aggregated data from the electronic health records of over 100 million patients contributed by US health care organizations. Results: Compared to propensity-score-matched children with other respiratory infections, children aged 1-10 years with COVID-19 had a higher risk of elevated transaminases (Hazard ratio (HR) (95% Confidence interval (CI)) 2.16 (1.74-2.69)) or total bilirubin (HR (CI) 3.02 (1.91-4.78)), or new diagnoses of liver diseases (HR (CI) 1.67 (1.21-2.30)) from one to six months after infection. Patients with pre-existing liver abnormalities, liver abnormalities surrounding acute infection, younger age (1-4 years), or illness requiring hospitalization all had similarly elevated risk. Children who developed liver abnormalities following COVID-19 had more pre-existing conditions than those who developed abnormalities following other infections. Conclusion: These results indicate that SARS-CoV-2 may prime the patient for subsequent development of liver infections or non-infectious liver diseases. While rare (~1 in 1,000), SARS-CoV-2 is a risk for subsequent abnormalities in liver function or the diagnosis of diseases of the liver.

Concepts Keywords
23295905doi Abnormalities
Education Acute
Hepatitis Cohorts
Sears Cov


Type Source Name
disease MESH abnormalities
disease MESH SARS-CoV-2 infection
pathway REACTOME SARS-CoV-2 Infection
disease MESH hepatitis
disease MESH etiology
disease MESH respiratory infections
disease MESH liver diseases
disease MESH infection
disease IDO acute infection
drug DRUGBANK Methylphenidate
disease VO Viruses
disease MESH viral infections
disease MESH influenza
disease IDO cell
disease VO population
disease VO USA
disease MESH complications
disease MESH pneumonia
disease VO vaccine
disease MESH alpha 1 antitrypsin deficiency
drug DRUGBANK L-Alanine
disease MESH cholestasis
disease MESH hepatic coma
disease MESH hepatic failure
disease IDO algorithm
disease VO vaccination
disease VO age

(Visited 1 times, 1 visits today)